Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

ImmunityBio Inc. Stock

Price
Target price
€5.29

€5.29

6.990%
0.346
6.990%
-
 
30.01.26 / Tradegate WKN: A2QQ2E / Name: ImmunityBio / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of ImmunityBio Inc. in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock ImmunityBio Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for ImmunityBio

sharewise wants to provide you with the best news and tools for ImmunityBio, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer: https://cdn.content.foolcdn.com/images/1umn9qeh/production/23fc1b822f8eafa9d627ca7fbac8d5b39aebf467-1401x1251.png?w=1401&h=1251
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label

TheMotleyFool 
0 26.01.26
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month: https://cdn.content.foolcdn.com/images/1umn9qeh/production/23fc1b822f8eafa9d627ca7fbac8d5b39aebf467-1401x1251.png?w=1401&h=1251
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month

ImmunityBio (NASDAQ:IBRX), an immunity-focused biotech, closed Friday’s session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.

Trading

TheMotleyFool 
0 24.01.26
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses: https://cdn.content.foolcdn.com/images/1umn9qeh/production/dbf4812d84ab78c74b512c7cb2e4d70bee11215c-1401x1251.png?w=1401&h=1251
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what to do

TheMotleyFool 
0 21.01.26
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer: https://cdn.content.foolcdn.com/images/1umn9qeh/production/23fc1b822f8eafa9d627ca7fbac8d5b39aebf467-1401x1251.png?w=1401&h=1251
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label

TheMotleyFool 
0 21.01.26
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year: https://cdn.content.foolcdn.com/images/1umn9qeh/production/dbf4812d84ab78c74b512c7cb2e4d70bee11215c-1401x1251.png?w=1401&h=1251
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year

ImmunityBio (NASDAQ:IBRX), cancer and infectious disease immunotherapy developer, closed Friday at $5.52, up 39.75% for the session. The stock climbed after Premarket updates highlighted explosive

TheMotleyFool 
0 16.01.26
Why ImmunityBio Stock Is Skyrocketing Again Today: https://g.foolcdn.com/editorial/images/851657/gettyimages-1205459956.jpg
Why ImmunityBio Stock Is Skyrocketing Again Today

Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible

TheMotleyFool 
0 16.01.26
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%: https://cdn.content.foolcdn.com/images/1umn9qeh/production/23fc1b822f8eafa9d627ca7fbac8d5b39aebf467-1401x1251.png?w=1401&h=1251
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%

ImmunityBio (NASDAQ:IBRX), a cancer and infectious-disease drug developer, closed Thursday at $3.95, up 30.79% for the session. The stock jumped after preliminary 2025 results highlighted roughly

TheMotleyFool 
0 15.01.26
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know: https://cdn.content.foolcdn.com/images/1umn9qeh/production/f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png?w=1401&h=1251
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know

Heights Capital Management recently established a new position in ImmunityBio (NASDAQ:IBRX), buying 6,565,709 shares valued at approximately $16.15 million.

Heights Capital Management disclosed a

TheMotleyFool 
0 19.11.25
IBRX Sales Soar 2,540%
IBRX Sales Soar 2,540%

ImmunityBio (NASDAQ:IBRX), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating

TheMotleyFool 
0 06.08.25